Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Predictors of weight loss… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Predictors of weight loss in adults with topiramate-treated epilepsy.

Artikel i vetenskaplig tidskrift
Författare Elinor Ben-Menachem
Mette Axelsen
Else Hellebö Johanson
Anna Stagge
Ulf Smith
Publicerad i Obesity research
Volym 11
Nummer/häfte 4
Sidor 556-62
ISSN 1071-7323
Publiceringsår 2003
Publicerad vid Institutionen för klinisk neurovetenskap, Sektionen för kliniska nervsjukdomar
Institutionen för invärtesmedicin, Avdelningen för internmedicin
Sidor 556-62
Språk en
Länkar www.ncbi.nlm.nih.gov/entrez/query.f...
Ämnesord Adult, Anticonvulsants, adverse effects, therapeutic use, Blood Glucose, analysis, Body Composition, drug effects, Body Mass Index, Cholesterol, blood, Energy Intake, Epilepsy, drug therapy, Female, Fructose, adverse effects, analogs & derivatives, therapeutic use, Glucose Tolerance Test, Humans, Leptin, blood, Male, Middle Aged, Obesity, physiopathology, Prospective Studies, Regression Analysis, Weight Loss, drug effects
Ämneskategorier Neurologi

Sammanfattning

OBJECTIVE: We examined predictors of weight loss with topiramate, an anticonvulsant associated with weight loss in adults. RESEARCH METHODS AND PROCEDURES: In this uncontrolled, prospective clinical trial, topiramate was added to existing anticonvulsants in adults (40 to 110 kg) with partial-onset seizures. Primary measurements were change from baseline weight after 3 months and 1 year in patients completing 1 year of topiramate treatment (N = 38). Physiological and metabolic measures were analyzed for correlation with weight loss during topiramate treatment. RESULTS: In patients who completed 1 year of topiramate treatment, baseline weight was reduced in 82% at 3 months and in 86% at 1 year. Mean body weight was reduced 3.0 kg (3.9% of baseline) at 3 months and 5.9 kg (7.3%) at 1 year. In obese patients [body mass index (BMI) >/= 30 kg/m(2)], mean weight loss was 4.2 kg (4.3%) at 3 months and 10.9 kg (11.0%) at 1 year. Weight loss was primarily caused by reduction in body fat mass. For all patients, weight loss at 3 months correlated most strongly with reduced caloric intake (p = 0.02). At 1 year, caloric intake had returned to baseline levels; weight loss correlated most strongly with higher baseline BMI (p = 0.0007). DISCUSSION: Our results suggest that weight loss occurs in most adults treated with topiramate and is sustained for at least 1 year. Reduced caloric intake may account, in part, for weight loss during early treatment. The pattern of weight loss differs according to baseline BMI, with obese patients experiencing greater weight loss during continued therapy.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?